Recent preclinical studies also demonstrate that BCMA-targeting agents trigger immunomodulatory effects to mitigate the immunosuppressive MM bone marrow (BM) microenvironment and prolonged animal survival when combined with current anti-MM drugs including bortezomib, immunomodulatory drugs (lenalidomide, pomalidomide), or CD38 MoAb daratumumab [13–16]. Here, CD38 is linked to Miyoshi myopathy.